Update on bevacizumab and other angiogenesis inhibitors for brain cancer

A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

(2017) David A. Reardon et al.   Journal of the National Comprehensive Cancer Network

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma

(2013) Peter S. LaViolette et al.   NEURO-ONCOLOGY

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

(2012) Quintino Giorgio D’Alessandris et al.   ACTA NEUROCHIRURGICA

Brain metastases: pathobiology and emerging targeted therapies

(2012) Matthias Preusser et al.   ACTA NEUROPATHOLOGICA

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

(2012) Søren Møller et al.   ACTA ONCOLOGICA

Mechanisms of Glioma-Associated Neovascularization

(2012) Matthew E. Hardee et al.   AMERICAN JOURNAL OF PATHOLOGY

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

(2012) Miguel J. Gil et al.   ANTI-CANCER DRUGS

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

(2012) D A Reardon et al.   BRITISH JOURNAL OF CANCER

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme

(2012) M J Paldino et al.   BRITISH JOURNAL OF RADIOLOGY

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

Bevacizumab Therapy May Contribute to Irradiation Deferral in Patients With Breast Cancer and With Central Nervous System Metastases: Findings of a Case Series

(2012) Panteleimon Kountourakis et al.   Clinical Breast Cancer

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

(2012) M. DeLay et al.   CLINICAL CANCER RESEARCH

Targeting Angiogenesis for Treatment of NSCLC Brain Metastases

(2012) C. Schettino et al.   CURRENT CANCER DRUG TARGETS

Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas

(2012) Katharina Seystahl et al.   EUROPEAN NEUROLOGY

Treatment of elderly patients with glioblastoma

(2012) David A Reardon   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

(2012) Alan Sandler et al.   LUNG CANCER

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

(2012) T. N. Kreisl et al.   NEURO-ONCOLOGY

Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

(2012) Aurélien Corroyer-Dulmont et al.   NEURO-ONCOLOGY

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors

(2012) T. S. Armstrong et al.   NEURO-ONCOLOGY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI

(2012) Mohammad Najafi et al.   PLoS One

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases

(2012) D. P. Kodack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial

(2012) Daigo Yamamoto et al.   OncoTargets and Therapy

Bevacizumab and daily temozolomide for recurrent glioblastoma

(2011) Annick Desjardins et al.   CANCER

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

(2011) J. J. Vredenburgh et al.   CLINICAL CANCER RESEARCH

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

(2011) Samuel A. Goldlust et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

(2011) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study

(2011) Kyung-Jae Park et al.   JOURNAL OF NEURO-ONCOLOGY

Lack of Angiogenesis in Experimental Brain Metastases

(2011) Edina Bugyik et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

(2011) W. Wu et al.   NEURO-ONCOLOGY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

(2011) T. N. Kreisl et al.   NEURO-ONCOLOGY

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

(2011) W. B. Pope et al.   NEUROLOGY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival

(2011) Jan-Karl Burkhardt et al.   World Neurosurgery

Introduction

(2010)   ANNALS OF ONCOLOGY

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer

(2010) J. J. Yin et al.   CANCER RESEARCH

Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma

(2010) Jing Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme

(2010) James J. Vredenburgh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

(2010) Alessandra B. Francesconi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Bevacizumab and Recurrent Malignant Gliomas: A European Perspective

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

(2010) Kevin C. De Braganca et al.   JOURNAL OF NEURO-ONCOLOGY

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

The Molecular Pathobiology of Metastasis to the Brain: A Review

(2010) Kara D. Beasley et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Management of hypertension in angiogenesis inhibitor-treated patients

(2009) H. Izzedine et al.   ANNALS OF ONCOLOGY

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

(2009) Jerry Y. Hsu et al.   BIODRUGS

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series

(2009) Sana Intidhar Labidi et al.   Clinical Breast Cancer

Bevacizumab Safety in Patients with Central Nervous System Metastases

(2009) B. Besse et al.   CLINICAL CANCER RESEARCH

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

(2009) J. M. L. Ebos et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Anaplastic Glioma: How to Prognosticate Outcome and Choose a Treatment Strategy

(2009) Lisa M. DeAngelis   JOURNAL OF CLINICAL ONCOLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Current concepts in the evaluation and management of WHO grade II gliomas

(2009) Joseph M. Piepmeier   JOURNAL OF NEURO-ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Circulating endothelial progenitor cells in malignant gliomas

(2009) Neysan Rafat et al.   JOURNAL OF NEUROSURGERY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

(2009) et al.   NEUROSURGERY

Current management of metastatic brain disease

(2009) Tulika Ranjan et al.   Neurotherapeutics

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Bevacizumab in the Treatment of a Patient with Metastatic Colorectal Carcinoma with Brain Metastases

(2008) Achala Bhaskara et al.   Clinical Colorectal Cancer

Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation

(2008) Jeremy Rees et al.   EUROPEAN JOURNAL OF RADIOLOGY

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

(2008) Abby B. Siegel et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

(2008) Tyler Y. Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

(2008) Sheikh A. Ali et al.   JOURNAL OF NEUROSURGERY

Novel anti-angiogenic therapies for malignant gliomas

(2008) Andrew D Norden et al.   LANCET NEUROLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Safety of anticoagulation use and bevacizumab in patients with glioma

(2008) Phioanh (Leia) Nghiemphu et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY